Boston Scientific

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Boston Scientific (Booth 3243) is featuring several oral contributions and poster presentations, all of which highlight its Taxus paclitaxel drug-eluting stent technology.

Among the presentations are:

  • A plenary session on Saturday, March 28, entitled "Health Related Quality of Life and U.S. Based Economic Outcomes of PCI With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel and Left Main Coronary Artery Disease: 1-Year Results From the SYNTAX Trial"
  • An oral presentation on Saturday, March 28, entitled "Revascularization With Cardiac Surgery Versus Paclitaxel-Eluting Stents in Patients With Diabetes and Metabolic Syndrome: 1-Year Results From the SYNTAX Study"
  • Five poster presentations on Sunday, March 29, entitled "Effect of Gender on One Year Outcomes in the SYNTAX Trial," "The Impact of Age on One Year Outcomes in the SYNTAX Trial," "Randomized Comparison of Everolimus-eluting and Paclitaxel-eluting Stents: Pooled analysis of Two-Year Clinical Follow-up from the SPIRIT II and III Trials," "Paclitaxel-Eluting Stents for the Treatment of Bare Metal Stent Restenosis: Three-Year Results of the TAXUS vs. ISR Trial" and "TAXUS ARRIVE Program: The Utility of a Comprehensive Drug-Eluting Stent Registry."